NH001

NH001 is a small molecule dopaminergic agonist being developed by NeuroHealing Pharmaceuticals for the treatment of patients in a vegetative state (VS) or minimally conscious state (MCS) following traumatic brain injury (TBI). The drug acts as a potent agonist at both D1 and D2 dopamine receptors, a mechanism intended to stimulate the brain's arousal systems and promote the recovery of consciousness in patients with severe brain injury. NH001 is a proprietary formulation of apomorphine, leveraging its well-established human safety profile while utilizing a non-invasive route of administration tailored for patients in post-traumatic coma. It has received FDA orphan drug designation and has an active Investigational New Drug (IND) application cleared for Phase 2 clinical evaluation.

Other names

intranasal apomorphine